Abbot (ABT) is a High Quality Company, Says Jim Cramer
Pharma giant Abbott Laboratories (NYSE:ABT)’s shares are down 15.9% over the past year and 12% year-to-date.
Abbott Laboratories (ABT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Impax Asset Management Ian Simm | 128,190 | $16,060,925 | -1% | 0.1% |
| 2. | Ayrshire Capital Management John Nevin Jr. | 40,525 | $5,077,344 | +8% | 2.33% |
| 3. | Zevenbergen Capital Investments Nancy Zevenbergen | 21,364 | $2,676,696 | +2% | 0.06% |
| 4. | Beech Hill Partners Paul Cantor, Joseph Weiss, And Will Wurm | 10,950 | $1,371,926 | 0.66% | |
| 5. | Hourglass Capital Kenneth A. Moffet | 10,000 | $1,252,900 | 0.27% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $107.13 | 18,800 | $2,013,966.92 | 216,203 | 2026-01-23 | Filing | |
| $122.50 | 2,040 | $249,900.00 | 7,296 | 2021-02-23 | Filing | |
| $73.40 | 2,000 | $146,798.20 | 52,562 | 2019-04-22 | Filing | |
| $72.32 | 100 | $7,231.50 | 6,400 | 2019-01-31 | Filing | |
| $72.31 | 100 | $7,230.50 | 6,300 | 2019-01-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $128.02 | 1,586 | $203,042.57 | 30,384 | 2025-11-25 | Filing | |
| $134.55 | 5,550 | $746,758.05 | 51,003 | 2025-08-08 | Filing | |
| $129.66 | 2,600 | $337,116.00 | 34,058 | 2025-04-30 | Filing | |
| $136.65 | 200 | $27,329.00 | 71,928 | 2025-03-07 | Filing | |
| $133.82 | 91,167 | $12,199,967.94 | 71,928 | 2025-03-06 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 14,519,346 | $1,819,128,861 | 0.59% | |
| 2. | 4,025,126 | $504,308,037 | 0.3% | |
| 3. | 3,125,000 | $391,531,250 | 4.2% | |
| 4. | 3,116,386 | $390,452,001 | 1.55% | |
| 5. | 2,688,282 | $336,814,847 | 0.72% |
News See All
14 Stocks on Jim Cramer's Radar
In a recent appearance on CNBC's Squawk on the Street, Jim Cramer discussed OpenAI's ChatGPT and business applications.
Evercore ISI Says Abbott’s (ABT) Core Growth Drivers Are Still Intact
On January 23, Evercore ISI trimmed its price target on Abbott Laboratories (NYSE:ABT) to $138 from $144. However, it kept an Outperform rating.
12 Most Profitable Dividend Stocks to Buy in 2026
Savita Subramanian, the firm’s head of US equity and quant strategy, pointed to a familiar timing pattern. Dividend growth typically trails earnings growth by roughly three quarters.
Abbott Laboratories (NYSE:ABT) Q4 2025 Earnings Call Transcript
Operator: Good morning, and thank you for standing by. Welcome to Abbott Laboratories' Fourth Quarter 2025 Earnings Conference Call.
Abbott Laboratories (ABT) Positioned to Benefit as Healthcare Sector Enters Recovery Phase
TheFly reported on January 9 that Bernstein analyst Lee Hambright raised ABT’s price target to $154 from $150, while maintaining an Outperform rating on the stock. The company noted that U.S.
10 Best Investments During A Recession
As of early 2026, the U.S. economy is in a fragile “stagflation-lite” phase, balancing resilient growth against an elevated risk of recession. According to major financial organizations like J.P.
Abbott (ABT) Wins FDA Approval for Volt PFA System in AFib Treatment
On December 22, Abbott Laboratories (NYSE:ABT) said the US Food and Drug Administration has approved the company’s Volt™ PFA System to treat patients with atrial fibrillation, or AFib.
14 Best Pharma Dividend Stocks to Buy in 2026
For most drugmakers, the US is the largest single market. Prices there are often close to three times higher than in other developed countries. Branded medicines carry even steeper premiums.
Can Abbott Laboratories (ABT) Deliver Resilient Returns in the Long Term?
Parnassus Investments, an investment management firm, released its “Parnassus Value Equity Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Hedge Fund Resource Center Billionaire Hedge Funds
